featured
Addition of Ganitumab Did Not Improve Survival in Metastatic Adenocarcinoma of the Pancreas
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Phase III Randomized, Double-Blind, Placebo-Controlled Trial of Ganitumab or Placebo in Combination With Gemcitabine as First-Line Therapy for Metastatic Adenocarcinoma of the Pancreas: The GAMMA Trial
Ann. Oncol 2015 May 01;26(5)921-927, CS Fuchs, S Azevedo, T Okusaka, JL Van Laethem, LR Lipton, H Riess, C Szczylik, MJ Moore, M Peeters, G Bodoky, M Ikeda, B Melichar, R Nemecek, S Ohkawa, A Świeboda-Sadlej, SA Tjulandin, E Van Cutsem, R Loberg, V Haddad, JL Gansert, BA Bach, A CarratoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.